Ovid Therapeutics (OVID) Profit After Tax (2016 - 2026)

Ovid Therapeutics has reported Profit After Tax for 11 years, with the latest figure at -$17.0 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 66.1% year-over-year to -$17.0 million; the trailing twelve-month figure through Mar 2026 stood at -$24.1 million (up 3.33% YoY), and the FY2025 full-year result was -$17.4 million, up 34.17% from the prior year.
• Profit After Tax for Q1 2026 stood at -$17.0 million, down from $9.7 million in the prior quarter.
• The five-year high for Profit After Tax was $9.7 million in Q4 2025, with the low at -$17.0 million in Q1 2026.
• Historically, Profit After Tax has averaged -$9.8 million across 5 years, with a median of -$12.0 million in 2022.
• The largest YoY upside for Profit After Tax was 204.83% in 2025 against a maximum downside of 154.97% in 2025.
• Ovid Therapeutics' Profit After Tax stood at -$11.5 million in 2022, then sank by 33.18% to -$15.3 million in 2023, then soared by 39.61% to -$9.3 million in 2024, then soared by 204.83% to $9.7 million in 2025, then sank by 275.26% to -$17.0 million in 2026.
• The last three Profit After Tax figures came in at -$17.0 million (Q1 2026), $9.7 million (Q4 2025), and -$12.2 million (Q3 2025), per Business Quant data.